DIKUL - logo
E-viri
Recenzirano Odprti dostop
  • G protein‐coupled receptor ...
    Hasenoehrl, Carina; Feuersinger, David; Sturm, Eva M; Bärnthaler, Thomas; Heitzer, Ellen; Graf, Ricarda; Grill, Magdalena; Pichler, Martin; Beck, Stephan; Butcher, Lee; Thomas, Dominique; Ferreirós, Nerea; Schuligoi, Rufina; Schweiger, Caroline; Haybaeck, Johannes; Schicho, Rudolf

    International journal of cancer, 1 January 2018, Letnik: 142, Številka: 1
    Journal Article

    The putative cannabinoid receptor GPR55 has been shown to play a tumor‐promoting role in various cancers, and is involved in many physiological and pathological processes of the gastrointestinal (GI) tract. While the cannabinoid receptor 1 (CB1) has been reported to suppress intestinal tumor growth, the role of GPR55 in the development of GI cancers is unclear. We, therefore, aimed at elucidating the role of GPR55 in colorectal cancer (CRC), the third most common cancer worldwide. Using azoxymethane (AOM)‐ and dextran sulfate sodium (DSS)‐driven CRC mouse models, we found that GPR55 plays a tumor‐promoting role that involves alterations of leukocyte populations, i.e. myeloid‐derived suppressor cells and T lymphocytes, within the tumor tissues. Concomitantly, expression levels of COX‐2 and STAT3 were reduced in tumor tissue of GPR55 knockout mice, indicating reduced presence of tumor‐promoting factors. By employing the experimental CRC models to CB1 knockout and CB1/GPR55 double knockout mice, we can further show that GPR55 plays an opposing role to CB1. We report that GPR55 and CB1 mRNA expression are differentially regulated in the experimental models and in a cohort of 86 CRC patients. Epigenetic methylation of CNR1 and GPR55 was also differentially regulated in human CRC tissue compared to control samples. Collectively, our data suggest that GPR55 and CB1 play differential roles in colon carcinogenesis where the former seems to act as oncogene and the latter as tumor suppressor. What's new? The cannabinoid receptor GPR55 may boost colon tumor growth, new results show. Earlier work has established the receptor's role in various cancers, but this study is the first to investigate its relationship to colorectal cancer. These authors observed that mice lacking GPR55 had a much lighter tumor burden than wild type mice, as well as lower levels of COX‐2 and STAT3, both of which help drive tumor growth. Knocking out GPR55 also bumped the infiltration of CD4+ and CD8+ T cells in the tumor microenvironment, suggesting that GPR55 aids cancer by arranging a friendlier leukocyte population around the tumor.